Nurix Therapeutics' (NRIX) "Overweight" Rating Reaffirmed at Stephens

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report)'s stock had its "overweight" rating reissued by research analysts at Stephens in a report issued on Thursday,Benzinga reports. They presently have a $30.00 price objective on the stock. Stephens' price target indicates a potential upside of 141.16% from the stock's current price.

A number of other analysts also recently weighed in on NRIX. Wells Fargo & Company cut their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Leerink Partners initiated coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Wall Street Zen raised shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. Finally, Needham & Company LLC reissued a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $29.59.

Nurix Therapeutics Trading Down 1.8%

NASDAQ NRIX traded down $0.23 during trading on Thursday, hitting $12.44. The company had a trading volume of 1,408,338 shares, compared to its average volume of 850,512. Nurix Therapeutics has a one year low of $8.18 and a one year high of $29.56. The company has a market cap of $951.04 million, a price-to-earnings ratio of -4.77 and a beta of 2.15. The company's fifty day moving average is $11.24 and its 200-day moving average is $13.76.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.27. The business had revenue of $44,056 billion during the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. As a group, equities analysts anticipate that Nurix Therapeutics will post -2.99 EPS for the current year.

Insider Activity

In other news, CFO Houte Hans Van sold 6,198 shares of the stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the transaction, the chief financial officer owned 33,724 shares in the company, valued at $382,092.92. This represents a 15.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the transaction, the insider owned 61,516 shares in the company, valued at $707,434. This trade represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,013 shares of company stock worth $137,096 in the last 90 days. Company insiders own 7.40% of the company's stock.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors have recently made changes to their positions in NRIX. Bank of New York Mellon Corp lifted its stake in shares of Nurix Therapeutics by 8.9% in the 4th quarter. Bank of New York Mellon Corp now owns 190,905 shares of the company's stock worth $3,597,000 after purchasing an additional 15,639 shares during the period. US Bancorp DE raised its stake in Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after acquiring an additional 842 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Nurix Therapeutics by 11.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 572,834 shares of the company's stock worth $10,792,000 after acquiring an additional 61,114 shares during the period. Victory Capital Management Inc. raised its stake in Nurix Therapeutics by 179.5% during the 4th quarter. Victory Capital Management Inc. now owns 60,212 shares of the company's stock worth $1,134,000 after acquiring an additional 38,672 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in Nurix Therapeutics during the 4th quarter worth approximately $376,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.